Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

BioLife Solutions Inc

Healthcare US BLFS

25.57USD
0.78(3.15%)

Last update at 2026-06-24T20:09:00Z

Day Range

24.7726.04
LowHigh

52 Week Range

17.8629.62
LowHigh

Fundamentals

  • Previous Close 24.79
  • Market Cap1080.47M
  • Volume1047098
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA3.61M
  • Revenue TTM96.21M
  • Revenue Per Share TTM2.02
  • Gross Profit TTM 62.12M
  • Diluted EPS TTM-0.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.08100M -11.42500M -18.47100M -144.82700M -28.68900M
Minority interest - - - - -
Net income -12.13000M -20.18400M -66.42700M -139.80500M -8.38300M
Selling general administrative 45.52M 40.54M 43.26M 47.67M 34.10M
Selling and marketing expenses 9.85M 9.61M 12.71M 21.57M 14.00M
Gross profit 62.12M 53.67M 46.75M 53.82M 37.75M
Reconciled depreciation 4.69M 8.66M 13.09M 16.47M 8.20M
Ebit - -7.12900M -57.53300M -39.91200M -30.36600M
Ebitda -9.37500M 1.53M -45.23800M -29.51300M -23.98300M
Depreciation and amortization - 8.66M 12.29M 10.40M 6.38M
Non operating income net other - - - - -
Operating income -12.13000M -7.12900M -23.44000M -39.91200M -30.36600M
Other operating expenses 108.34M 89.38M 99.30M 201.67M 149.52M
Interest expense 2.71M 0.72M 1.81M 0.69M -0.43200M
Tax provision 0.05M -0.03800M 0.13M -5.02200M -20.30600M
Interest income - - - - -
Net interest income 2.71M -0.71900M -1.74200M -0.68700M -0.43200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M -0.03800M 0.02M -5.02200M -20.30600M
Total revenue 96.21M 82.25M 75.86M 161.76M 119.16M
Total operating expenses 74.25M 60.80M 117.58M 93.73M 68.11M
Cost of revenue 34.10M 28.58M 96.52M 107.94M 81.41M
Total other income expense net 0.05M -4.29600M 4.97M -104.91500M 1.68M
Discontinued operations - - - - -
Net income from continuing ops -12.13000M -11.38700M -102.23400M -139.80500M -8.38300M
Net income applicable to common shares - - - -139.80500M -8.38300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 405.88M 399.49M 412.71M 450.23M 552.60M
Intangible assets 4.26M 9.56M 21.15M 32.09M 152.15M
Earning assets - - - - -
Other current assets -6.85800M 6.00M 6.76M 74.39M 97.51M
Total liab 34.00M 50.58M 75.05M 86.04M 71.85M
Total stockholder equity 371.89M 348.91M 337.66M -246.91500M 480.75M
Deferred long term liab - - - - -
Other current liab 14.25M 12.35M 24.57M 23.84M 20.44M
Common stock 0.05M 0.05M 0.04M 0.04M 0.04M
Capital stock 0.05M 0.05M 0.04M 0.04M 0.04M
Retained earnings -339.69600M -335.10100M -313.34200M -246.91500M -105.02000M
Other liab - - - 2.58M 31.88M
Good will 208.59M 212.30M 224.74M 224.74M 224.74M
Other assets - - - 386.16M 426.75M
Cash 33.04M 95.39M 35.44M 19.44M 69.87M
Cash and equivalents - - - - -
Total current liabilities 22.98M 32.73M 42.18M 44.58M 39.97M
Current deferred revenue - 0.10M 0.66M 0.55M 0.81M
Net debt -15.14100M -65.21200M 7.25M 24.27M -42.99100M
Short term debt 7.24M 12.45M 10.01M 4.83M 3.77M
Short long term debt 5.00M 10.94M 6.83M 1.81M 0.86M
Short long term debt total 17.90M 30.17M 42.69M 43.71M 26.88M
Other stockholder equity 711.40M 683.94M 651.30M 0.64M 586.01M
Property plant equipment - - - - 46.61M
Total current assets 120.18M 148.76M 120.60M 138.45M 125.86M
Long term investments 31.25M 5.62M 5.62M 6.40M 4.37M
Net tangible assets - - - 364.19M 480.75M
Short term investments 55.89M 9.20M 16.29M 43.26M -
Net receivables 7.95M 9.17M 18.66M 33.94M 23.22M
Long term debt - 5.00M 18.31M 23.79M 6.35M
Inventory 30.16M 29.01M 43.46M 34.90M 28.34M
Accounts payable 1.49M 3.57M 6.94M 15.37M 14.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.13M 0.02M -0.34500M -0.67900M -0.28200M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 41.61M 6.48M 0.27M 9.35M 9.81M
Deferred long term asset charges - - - - -
Non current assets total 285.71M 250.73M 292.11M 311.78M 426.75M
Capital lease obligations 12.90M 14.23M 17.55M 18.11M 19.66M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -74.47000M 58.30M -1.01400M -58.11700M -12.64200M
Change to liabilities - - - 0.00000M 2.02M
Total cashflows from investing activities -71.53900M 58.30M - -58.11700M -12.64200M
Net borrowings -10.00000M -6.60800M - - -2.89400M
Total cash from financing activities -10.92400M -6.78300M 10.59M 16.32M -2.77800M
Change to operating activities - - - 1.99M 4.47M
Net income -4.59500M -20.18400M -66.42700M -139.80500M -7.63500M
Change in cash -62.34800M 59.95M 15.96M -50.39700M -20.58600M
Begin period cash flow 95.39M 35.44M 19.47M 69.87M 90.46M
End period cash flow 33.04M 95.39M 35.44M 19.47M 69.87M
Total cash from operating activities 20.11M 8.43M -12.49800M -8.48900M -4.83600M
Issuance of capital stock 0.00000M 0.00000M 10.24M 0.00000M -0.13000M
Depreciation 4.69M 5.49M 12.29M 16.47M 12.87M
Other cashflows from investing activities -71.53900M -2.36800M - -58.11700M -12.64200M
Dividends paid - - - - -
Change to inventory -1.26800M 0.78M -8.55200M -6.55900M 0.11M
Change to account receivables 0.26M -2.89900M 15.35M -10.75300M -10.13200M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.94200M -0.37700M 0.84M -1.52000M 0.12M
Change to netincome - - - 114.79M -8.96600M
Capital expenditures 9.48M 3.23M 6.38M 10.38M 8.38M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -8.90900M 0.23M 1.47M -14.90500M -3.53100M
Stock based compensation 22.99M 30.92M 31.67M 25.33M 13.96M
Other non cash items 29.02M -7.96200M 8.56M 109.65M -0.36400M
Free cash flow 10.64M 5.20M -18.87900M -18.87400M -13.22100M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BLFS
BioLife Solutions Inc		 0.78 3.15% 25.57 - 196.08 11.23 2.90 10.49 70.89
ISRG
Intuitive Surgical Inc		 -1.35 0.33% 401.83 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 -0.25 0.13% 190.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.33 0.34% 95.33 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.85 2.68% 147.77 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

BioLife Solutions Inc

3303 Monte Villa Parkway, Bothell, WA, United States, 98021

Key Executives

Name Title Year Born
Mr. Michael P. Rice Chairman & CEO 1963
Mr. Roderick de Greef Pres & COO 1960
Mr. Troy Wichterman Chief Financial Officer 1985
Dr. Aby J. Mathew Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer 1972
Mr. Marcus Schulz Chief Revenue Officer 1979
Mr. Todd Berard Chief Marketing Officer 1969
Ms. Sarah Aebersold J.D. VP of Global HR 1976
Ms. Karen Foster Chief Quality Officer 1960
Mr. Roderick de Greef CEO & Chairman 1960
Ms. Karen Foster Chief Quality & Operations Officer 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.